Clinical Trials Browser

OTHER × Pharmacogenomic Variants × 1 year × Clear all

NCT03506373 2026-05-05

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Phase 2 Terminated

21 enrolled 11 charts

Waldenstrom Macroglobulinemia

NCT03537690 2026-04-29

FID-007 in Treating Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT03479268 2026-04-27

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Prolymphocytic, B-Cell

NCT01165333 2026-03-16

CILENT

Phase 1 Completed

Diffuse Intrinsic Pontine Glioma, Glioma

NCT03582124 2026-02-10

Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery

Phase 1/2 Recruiting

Lung Neoplasms

NCT03225664 2026-01-16

Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03259503 2025-11-10

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Phase 1 Completed

Hodgkin Disease, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse